statistiche ricercatore

Continente	#
NA - Nord America	1.180
EU - Europa	381
AS - Asia	317
AF - Africa	19
SA - Sud America	6
Continente sconosciuto - Info sul continente non disponibili	2
OC - Oceania	2
Totale	1.907

Nazione	#
US - Stati Uniti d'America	1.156
CN - Cina	187
IT - Italia	146
DE - Germania	50
JP - Giappone	35
GB - Regno Unito	30
FR - Francia	29
CA - Canada	21
SE - Svezia	20
ES - Italia	18
IE - Irlanda	17
TR - Turchia	17
UA - Ucraina	16
IN - India	14
TW - Taiwan	14
VN - Vietnam	11
KR - Corea	10
RU - Federazione Russa	10
ZA - Sudafrica	10
EG - Egitto	9
HK - Hong Kong	8
NL - Olanda	8
CZ - Repubblica Ceca	7
ID - Indonesia	7
FI - Finlandia	6
IR - Iran	5
BA - Bosnia-Erzegovina	4
PL - Polonia	4
CL - Cile	3
DK - Danimarca	3
GR - Grecia	3
TH - Thailandia	3
AU - Australia	2
BE - Belgio	2
BR - Brasile	2
MX - Messico	2
PH - Filippine	2
PT - Portogallo	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
AR - Argentina	1
AT - Austria	1
CR - Costa Rica	1
EU - Europa	1
IL - Israele	1
JO - Giordania	1
LT - Lituania	1
MD - Moldavia	1
MY - Malesia	1
RS - Serbia	1
SG - Singapore	1
SK - Slovacchia (Repubblica Slovacca)	1
Totale	1.907

Nome	#
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients, file e31e124d-c4ca-987f-e053-3705fe0a095a	667
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer, file e31e124d-9653-987f-e053-3705fe0a095a	241
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma, file e31e124d-9655-987f-e053-3705fe0a095a	216
Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy, file e31e124d-81ee-987f-e053-3705fe0a095a	214
GD2 expression in breast cancer., file e31e124c-b26e-987f-e053-3705fe0a095a	173
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib, file e31e124d-c0ca-987f-e053-3705fe0a095a	162
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA, file e31e124d-35ff-987f-e053-3705fe0a095a	159
Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response, file e31e124d-f529-987f-e053-3705fe0a095a	120
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients, file e31e124f-2e05-987f-e053-3705fe0a095a	25
Totale	1.977

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	58	0	0	0	0	0	0	0	0	0	0	33	25
2019/2020	399	18	18	32	42	41	35	60	37	44	23	30	19
2020/2021	546	24	28	24	41	45	58	29	46	44	100	70	37
2021/2022	485	47	49	49	55	42	32	27	19	24	28	84	29
2022/2023	300	16	32	58	28	28	50	27	5	14	12	23	7
2023/2024	134	14	13	21	11	13	8	12	18	17	7	0	0
Totale													1.977